Evidence map›Paper›PMID 39804194›Full record

ArticleHematological oncology2025

MicroRNA Profiling of Bone Marrow Plasma Extracellular Vesicles in Multiple Myeloma, Extramedullary Disease, and Plasma Cell Leukemia.

Jana Gregorova, Monika Vlachova, Petra Vychytilova-Faltejskova, Adela Dostalova, Tereza Ruzickova, Marek Vecera, Lenka Radova, Vendula Pospichalova, Stanislava Sladecek, Martina Hyzdalova and 12 more

Abstract read
In one paragraph

Article in Hematological oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Extramedullary Disease-Achilles Heel in Myeloma?American journal of hematology · 2026
    Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Jana GregorovaBabak Myeloma Group, Department of Pathophysiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Monika VlachovaBabak Myeloma Group, Department of Pathophysiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Petra Vychytilova-FaltejskovaCentre for Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
Adela DostalovaBabak Myeloma Group, Department of Pathophysiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Tereza RuzickovaBabak Myeloma Group, Department of Pathophysiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Marek VeceraCentre for Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.ORCID https://orcid.org/0000-0001-7510-3694
Lenka RadovaCentre for Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
Vendula PospichalovaDepartment of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.ORCID https://orcid.org/0000-0002-5957-2156
Stanislava SladecekDepartment of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
Martina HyzdalovaDepartment of Pharmacology and Toxicology, Veterinary Research Institute, Brno, Czech Republic.ORCID https://orcid.org/0000-0003-0269-0212
Jana KotaskovaDepartment of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic.
Marie JarosovaDepartment of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic.ORCID https://orcid.org/0000-0002-2194-3433
Josef MasekDepartment of Pharmacology and Toxicology, Veterinary Research Institute, Brno, Czech Republic.
Klara BenesovaFaculty of Medicine, Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic.
Jiri JarkovskyFaculty of Medicine, Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic.
Lucie RihovaDepartment of Clinical Hematology, University Hospital Brno, Brno, Czech Republic.
Renata BezdekovaDepartment of Clinical Hematology, University Hospital Brno, Brno, Czech Republic.
Martina AlmasiDepartment of Clinical Hematology, University Hospital Brno, Brno, Czech Republic.
Ivanna BoichukDepartment of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic.
Martin StorkDepartment of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic.
Ludek PourDepartment of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic.
Sabina SevcikovaBabak Myeloma Group, Department of Pathophysiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.ORCID https://orcid.org/0000-0002-7194-6771

Funding

European unionFakultni nemocnice BrnoLékařská fakulta, Masarykova univerzitaMinisterstvo Zdravotnictví Ceské Republiky
6 · The paper itself

Abstract

Multiple myeloma is a plasma cell malignancy characterized by an abnormal increase in monoclonal immunoglobulins. Despite significant advances in treatment, some patients progress to more aggressive forms of multiple myeloma, including extramedullary disease or plasma cell leukemia. Although the exact molecular mechanisms are not known, several studies have confirmed the involvement of small extracellular vesicle-enriched microRNAs in multiple myeloma progression. Therefore, we performed expression profiling of these molecules in bone marrow plasma of multiple myeloma, extramedullary disease, and plasma cell leukemia patients using small RNA sequencing to identify novel molecules involved in disease pathogenesis. In total, 42 microRNAs were significantly dysregulated among analyzed subgroups. Independent validation by RT-qPCR confirmed elevated levels of miR-140-3p, miR-584-5p, miR-191-5p, and miR-143-3p in multiple myeloma patients compared to extramedullary disease and plasma cell leukemia patients. Subsequent statistical analysis revealed significant correlations between patient clinical characteristics or flow cytometry parameters and microRNA expression. These results indicate that dysregulation of microRNAs could contribute to multiple myeloma progression.

Indexed as

Bone MarrowExtracellular VesiclesLeukemia, Plasma CellMicroRNAsMultiple MyelomaAdultAgedBiomarkers, TumorFemaleGene Expression ProfilingHumansMaleMiddle AgedPlasma CellsBiomarkers, TumorMicroRNAsextramedullary diseasemicroRNAsmultiple myelomaplasma cell leukemiasmall extracellular vesiclessmall RNA sequencing

Identifiers

PMID39804194
PMCPMC11727818

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.